Latest ABVD Stories
A multicenter trial showed that nearly half of young patients with early-stage Hodgkin lymphoma can be cured without undergoing either irradiation or intensive chemotherapy that would leave them at risk for second cancers, infertility, heart and other problems later.
The largest study ever on the effect of genetic variability on the toxicity of chemotherapy in breast cancer shows that it is possible to predict which patients are most likely to suffer serious side effects.
New research led by the NCIC Clinical Trials Group (CTG) at Queen’s University has proven patients with limited stage Hodgkin’s lymphoma have a better chance of long-term survival if they undergo a standard chemotherapy regimen as opposed to radiation-based treatment.
Lymphoma and myeloma are both malignant diseases that arise from lymphocytes, a subset of blood cells, and commonly involve lymph nodes and the bone marrow.
Development of a predictive test that included genomic signatures that indicated chemoresistance, chemosensitivity and endocrine sensitivity for women with newly diagnosed breast cancer identified patients with an increased likelihood of survival following chemotherapy.
A breakthrough by scientists at Queen's University Belfast could help reduce heart failure in cancer patients around the world, and ultimately increase survival rates.
ORLANDO, Fla., Dec. 5, 2010 /PRNewswire-USNewswire/ -- The next generation of drug therapies and enhanced treatment approaches for various forms of lymphoma are evolving as researchers continue to better understand how these cancers progress.
A lower dose of radiation used to reduce side effects is not as effective as the regular dose when given with the standard chemotherapy in the treatment of Hodgkin's lymphoma patients with early, intermediate-stage disease.
WASHINGTON, July 1 /PRNewswire-USNewswire/ -- Older patients with Hodgkin lymphoma (HL) and a history of heart disease face a high risk of hospitalization for cardiac complications after completing treatment, according to research published online today in Blood, the journal of the American Society of Hematology.
- A person in a secondary role, specifically the second most important character (after the protagonist).